{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:14Z","timestamp":1787243354540,"version":"build-2736575974"},"reference-count":49,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER-1 and DISCOVER-2 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with active PsA (n = 1120; biologic-na\u00efve except 118 patients treated with tumor necrosis factor inhibitors in DISCOVER-1) were randomized to subcutaneous guselkumab 100 mg every 4 weeks (Q4W) or at Week 0, Week 4, then every 8 weeks (Q8W); or placebo. At Week 24, patients in the placebo group switched to guselkumab 100 mg Q4W. Treatment continued through 1Y and 2 years for DISCOVER-1 and DISCOVER-2, respectively. In this pooled analysis, patients with \u2265 1 adverse event (AE) through 1Y were standardized for 100 patient-years [100 PYs] of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through Week 24, adverse events (AEs) were consistent between patients treated with placebo and guselkumab (Q4W + Q8W). AEs were 142.8\/100 PYs and 150.6\/100 PYs, serious AEs were 7.1\/100 PYs and 4.4\/100 PYs, and AEs leading to study agent discontinuation were 4.1\/100 PYs and 3.8\/100 PYs, respectively. Through 1Y in patients treated with guselkumab, no uveitis, active tuberculosis, opportunistic infections, or inflammatory bowel disease were observed, and low rates of malignancy and major adverse cardiovascular (CV) events were observed. Injection-site reactions occurred in 1.7%, and antibodies to guselkumab in 4.5% of patients treated with guselkumab through 1Y; the vast majority of antibodies to guselkumab were nonneutralizing. Serum hepatic transaminase elevations (more common with Q4W than Q8W dosing) and decreased neutrophil counts were generally mild, transient, and did not require treatment discontinuation, with minimal change from Week 24 to 1Y.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Guselkumab 100 mg Q4W and Q8W were well tolerated in patients with PsA, with no new safety concerns through 1Y of the phase III DISCOVER trials. Guselkumab safety through 1Y in patients with PsA is consistent with that established in patients with psoriasis who were treated with guselkumab. [ClinicalTrials.gov:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03162796\">NCT03162796<\/jats:ext-link>\n                      and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03158285\">NCT03158285<\/jats:ext-link>\n                      ]\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.201532","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T08:20:25Z","timestamp":1619857225000},"page":"1815-1823","source":"Crossref","is-referenced-by-count":31,"title":["Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis"],"prefix":"10.3899","volume":"48","author":[{"given":"Proton","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasheen","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraneedharan","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"2023010522252298000_48.12.1815.1","unstructured":"Tremfya [package insert] . Horsham, PA: Janssen Biotech, Inc.; 2020."},{"key":"2023010522252298000_48.12.1815.2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40257-018-0406-1","article-title":"Guselkumab: a review in moderate to severe plaque psoriasis","volume":"19","author":"Al-Salama","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2023010522252298000_48.12.1815.3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00011-020-01339-9","article-title":"Interleukin 23 and autoimmune diseases: current and possible future therapies","volume":"69","author":"Abdo","year":"2020","journal-title":"Inflamm Res"},{"key":"2023010522252298000_48.12.1815.4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41584-019-0285-8","article-title":"Bedside to bench: defining the immunopathogenesis of psoriatic arthritis","volume":"15","author":"Bravo","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2023010522252298000_48.12.1815.5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010522252298000_48.12.1815.6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207577200"},{"key":"2023010522252298000_48.12.1815.7","doi-asserted-by":"publisher","DOI":"10.1038\/ni1497"},{"key":"2023010522252298000_48.12.1815.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"2023010522252298000_48.12.1815.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"2023010522252298000_48.12.1815.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2023010522252298000_48.12.1815.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"2023010522252298000_48.12.1815.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2023010522252298000_48.12.1815.13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023010522252298000_48.12.1815.14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457"},{"key":"2023010522252298000_48.12.1815.15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.clinthera.2019.04.030","article-title":"Impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis","volume":"41","author":"Costello","year":"2019","journal-title":"Clin Ther"},{"key":"2023010522252298000_48.12.1815.16","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2011.653646"},{"key":"2023010522252298000_48.12.1815.17","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023010522252298000_48.12.1815.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"2023010522252298000_48.12.1815.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546630252775162","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","volume":"13","author":"Griffiths","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2023010522252298000_48.12.1815.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040"},{"key":"2023010522252298000_48.12.1815.21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase II\/III clinical development programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"key":"2023010522252298000_48.12.1815.22","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2023010522252298000_48.12.1815.23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/14740338.2020.1763299","article-title":"Concerns about the safety of anti-TNF agents when treating rheumatic diseases","volume":"19","author":"Atzeni","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2023010522252298000_48.12.1815.24","unstructured":"Stelara [package insert] . Horsham, PA: Janssen Biotech, Inc.; 2019."},{"key":"2023010522252298000_48.12.1815.25","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"2023010522252298000_48.12.1815.26","unstructured":"Cosentyx [package insert] . East Hanover, NJ: Novartis; 2018."},{"key":"2023010522252298000_48.12.1815.27","unstructured":"Taltz [package insert] . Indianapolis, IN: Eli Lilly and Company; 2020."},{"key":"2023010522252298000_48.12.1815.28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","article-title":"Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers","volume":"84","author":"de La Forest Divonne","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2023010522252298000_48.12.1815.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.04.003"},{"key":"2023010522252298000_48.12.1815.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11142.x"},{"key":"2023010522252298000_48.12.1815.31","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8909834"},{"key":"2023010522252298000_48.12.1815.32","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections","volume":"6","author":"Kamm\u00fcller","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"2023010522252298000_48.12.1815.33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010522252298000_48.12.1815.34","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jdv.16460","article-title":"Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 and VOYAGE 2 trials","volume":"34","author":"Puig","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010522252298000_48.12.1815.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2023010522252298000_48.12.1815.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2023010522252298000_48.12.1815.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2023010522252298000_48.12.1815.38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2023010522252298000_48.12.1815.39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023010522252298000_48.12.1815.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"2023010522252298000_48.12.1815.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"2023010522252298000_48.12.1815.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"2023010522252298000_48.12.1815.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"2023010522252298000_48.12.1815.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707449"},{"key":"2023010522252298000_48.12.1815.45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"2023010522252298000_48.12.1815.46","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"2023010522252298000_48.12.1815.47","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000723"},{"key":"2023010522252298000_48.12.1815.48","doi-asserted-by":"crossref","unstructured":"Fieldhouse KA , Ukaibe S , Crowley EL , Khanna R , O\u2019Toole A , Gooderham MJ . Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context 2020;9:2020-2-1.","DOI":"10.7573\/dic.2020-2-1"},{"key":"2023010522252298000_48.12.1815.49","doi-asserted-by":"crossref","unstructured":"Blauvelt A , Gordon K , Griffiths CEM , Papp KA , Foley P , Song M , . Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment. Poster presented at: American Academy of Dermatology; 2021 April 23-25.","DOI":"10.1016\/j.jaad.2021.06.708"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.201532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T01:38:14Z","timestamp":1672969094000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.201532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,1]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.3899\/jrheum.201532"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.201532","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}